COGT — Cogent Biosciences Balance Sheet
0.000.00%
- $668.34m
- $381.26m
Annual balance sheet for Cogent Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 242 | 220 | 259 | 266 | 287 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0 | — | — | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 245 | 223 | 265 | 271 | 296 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4.75 | 4.48 | 31.1 | 30.3 | 26.6 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 251 | 232 | 301 | 313 | 328 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 13.1 | 17.1 | 26.8 | 38.2 | 55.7 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 16.2 | 17.9 | 45.1 | 55.6 | 71.6 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 235 | 214 | 256 | 258 | 256 |
Total Liabilities & Shareholders' Equity | 251 | 232 | 301 | 313 | 328 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |